Is hair thinning on cagrilintide dose-dependent or dose-rate dependent?

Details up front: hair thinning · cagrilintide.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

Why does this happen, and what would falsify the usual explanation?

The honest answer is that it resolves in most cases within six to nine months and that the resolution cannot be hurried much.

The trigger in this context is the rate of weight loss and the associated nutritional deficit, not a pharmacological property. The same phenomenon is well documented after bariatric surgery, illness and childbirth.

Gastrointestinal adverse events, indicative pooled rates

Ranges span agents and doses; read the specific prescribing information for a specific figure.

Worth being precise here: adequate protein matters. Hair is largely keratin, and follicles are among the most metabolically active tissues, so they are early casualties of a substantial protein shortfall.

The two-to-four-month latency follows directly from the duration of the telogen phase and is the diagnostic feature of the condition.

Research-use compounds are not approved for human use.

The trigger is the rate of loss, not the compound. Slowing it helps future follicles.

Worth being precise here: patterned rather than diffuse loss is a different condition and points elsewhere.

Recovery follows the same timeline in reverse: shedding stops within a few months of the trigger resolving, and visible density returns over six to twelve months as regrowth reaches length.

It is diffuse: increased shedding across the whole scalp, often noticed in the shower or on a brush, without a receding hairline or a defined crown pattern. Patterned loss is androgenetic and unrelated.

Recovery of density over six to twelve months is the typical reported course where the trigger has resolved.

The caveat is that patterned loss, scalp inflammation, scarring or loss with other systemic symptoms is a dermatological problem and not this.

It resolves in most cases over six to twelve months. That is genuinely the answer.

The short version: diffuse rather than patterned, delayed rather than immediate, self-limiting, and driven by the rate of loss rather than by the compound.

In telogen effluvium a stressor shifts a large fraction of follicles from anagen into telogen simultaneously. Because telogen lasts around two to three months, the shed appears two to four months after the trigger rather than during it.

Worth checking: ferritin, thyroid function and vitamin D. Low ferritin in particular is associated with shedding at levels that are not low enough to cause anaemia.

Nothing here is medical advice.

Check ferritin, thyroid and vitamin D once, then stop investigating.

edited 1 Apr 2025 by esther_vandeVelde — added the placebo-arm figures

This is one of the most distressing reported effects and one of the most reliably temporary.

Nothing topical has strong evidence for accelerating recovery from telogen effluvium specifically, as distinct from androgenetic loss where the evidence is entirely different.

Low ferritin is associated with increased shedding in observational studies at thresholds above those used to define anaemia.

Supplementing without a measured deficiency has no evidence behind it here and is not harmless at high doses.

Protein intake is the modifiable nutritional factor worth attending to.

edited 17 Apr 2025 by rhian_prydderch — updated for the 2026 guidance change

Answering this needs the rate of weight loss and the protein intake, since those are the two modifiable contributors.

Slowing the rate of weight loss reduces the severity of the trigger. It does not reverse a shed already in progress, because the follicles have already committed.

Telogen effluvium following rapid weight loss is well documented in the dermatological literature, including extensive description after bariatric surgery.

The caveat that actually matters: this is pattern recognition from published data, not a clinical assessment of you. Anything severe, persistent or accompanied by systemic features belongs with a clinician the same day.

Diffuse and delayed means telogen effluvium. Patterned means something else.